Ampio Pharmaceuticals Files FormRW To Terminate That Certain At The Marketing Offering Agreement, Dated September 18, 2023

Benzinga ·  Feb 29 04:51

- SEC Filing

On February 26, 2024, Ampio Pharmaceuticals, Inc. (the "Company") provided a notice to H.C. Wainwright & Co., LLC to terminate that certain At The Marketing Offering Agreement, dated September 18, 2023, by and between the Company and H.C. Wainwright & Co., LLC (the "ATM Agreement"), establishing an at-the-market equity distribution program for the offer and sale from time to time shares of the Company's common stock, par value $0.0001. In accordance with the ATM Agreement, the termination will be effective March 6, 2024.

In connection with the termination of the ATM Agreement, the Company filed on February 28, 2024 a post-effective amendment to its Registration Statement on Form S-3 (File No. 333-274558) to withdraw and remove from registration any and all Company securities that remain unsold or otherwise unissued under such Registration Statement, including shares of the Company's common stock that were covered by the at-the-market offering agreement prospectus filed as part of the Registration Statement.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment